Aug 4, 2009|
The world is watching the US
While it will be a while before the US economy gets back on its feet, the good news seems to be that the worst may be over for the world's largest economy. As reported on Moneynews, the IMF expects US' GDP to shrink by 2.6% in 2009 and then rise by 0.8% in 2010. Obviously, the stimulus packages announced by the Obama administration appear to have played a significant role in lending some semblance of stability to the economy. However, there are still many challenges that still persist. One is that unemployment has shown no signs of abating and therefore unless incomes of the people do not pick up, consumption, the biggest driver of the US economy will remain subdued. The most important and difficult issue facing the US government is the timing with respect to unwinding of the fiscal and monetary stimulus measures. Unless and until there are signs that a sustainable recovery is on the cards, the US exit from stimulus program would have to wait. And the problem is that nobody knows when a sustainable recovery will actually take place other than that it will be gradual and painful.
A recovery in the US will also do the global economy a world of good for it would mean a pickup in global trade and a booster shot to many countries around the world, mainly those who rely on exports. And while India is not as dependent as some other Asian economies on exports as it has a robust domestic market, a revival in exports will certainly help now more than ever as it has the problem of deficient monsoons to deal with. But given the state of the developed nations at present, a full-fledged export recovery does not appear to happen anytime soon.
Paying the price for cheaper drugs
Healthcare is an important issue for most of the nations across the world and 'affordable healthcare' the most important of them all. So who is paying the price for cheaper drugs around the world? Well, it is the US. With mounting research budgets on one hand and government pressure to reduce costs on the other, global pharma companies are finding it increasingly difficult to recover their costs of R&D. What is more, while prices of drugs in the US are freely determined, elsewhere across the world, it is the government which decides them, meaning that people outside of the US are getting medicines for which bulk of the R&D has been done in the US.
The problem is that Big Pharma are not able to replenish their pipelines with new drugs that can cover R&D costs or for that matter ward off the threat of generic competition. So they are either going in for big ticket mergers or acquiring promising drug pipelines or smaller biotech companies in need of funds. Indian companies focusing more on generics stand to benefit in terms of the increased focus on affordable healthcare and the potential in terms of the number of drugs going off patent in the future. But of course, this comes at a heavy price, namely increasing competition and brutal price erosion.
More Views on News
Jun 10, 2017
Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.
Aug 16, 2017
All across the country, the old gods become devils. New, gluten-free gods take their places...
Aug 16, 2017
And what it has in common with beating the stock market too.
Aug 16, 2017
Ensure your financial Independence, and pledge to start the journey towards financial freedom today!
Aug 14, 2017
Last week's correction is making a number of Super Investor stocks look a lot more attractive...
More Views on News
Aug 7, 2017
The data tells us quite a different story from the one the government is trying to project.
Aug 4, 2017
The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 7, 2017
Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407